![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217071
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216842
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-ertugliflozin-1646027922.pdf
https://www.fiercepharma.com/pharma/esc-merck-s-steglatro-makes-case-for-heart-failure-new-hospitalization-data
https://investors.merck.com/news/press-release-details/2020/Merck-and-Pfizers-SGLT2-Inhibitor-STEGLATROTM-ertugliflozin-Meets-Primary-Endpoint-in-VERTIS-CV-Trial-for-Patients-with-Type-2-Diabetes-and-Atherosclerotic-Cardiovascular-Disease/default.aspx
https://www.fiercepharma.com/pharma/ada-merck-pfizer-s-steglatro-rings-up-cv-safety-win-but-it-still-lags-heart-helping-peers
https://www.fiercepharma.com/pharma/ada-merck-pfizer-s-steglatro-rings-up-cv-safety-win-but-it-still-lags-heart-helping-peers
http://www.pharmatimes.com/news/nice_recommendation_for_steglatro_in_type_ii_diabetes_1282725
http://www.pharmatimes.com/news/smc_oks_four_meds_for_nhs_use,_including_roches_perjeta_1275014
https://www.forbes.com/sites/brucelee/2018/09/01/how-one-class-of-diabetes-medications-may-lead-to-flesh-eating-genital-infections/#62b120f17619
https://www.fiercepharma.com/pharma/fda-slaps-new-gangrene-warning-popular-sglt2-diabetes-drugs-from-lilly-j-j-and-more
https://www.tga.gov.au/prescription-medicines-registration-new-chemical-entities-australia
https://www.pharmacompass.com/pdf/news/merck-sharp-dohmes-steglatro-ertugliflozin-receives-approval-in-europe-1523363293.pdf
https://www.pharmacompass.com/pdf/news/msds-segluromet-ertugliflozinmetformin-hydrochloride-receives-approval-in-europe-1523363573.pdf
https://www.ema.europa.eu/documents/overview/steglujan-epar-medicine-overview_en.pdf
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/01/news_detail_002888.jsp&mid=WC0b01ac058004d5c1
https://www.reuters.com/article/us-merck-co-pfizer-ema/ema-panel-recommends-merck-pfizers-diabetes-drug-idUSKBN1FF1LU
http://www.pharmatimes.com/news/us_green_light_for_pfizermerck_diabetes_therapies_1215005
http://www.pmlive.com/pharma_news/fdas_year-end_approvals_take_annual_tally_to_46_1215003
http://www.nasdaq.com/article/how-large-is-mercks-phase-3-drug-pipeline-cm898499
https://www.bloomberg.com/news/articles/2017-12-21/steglujan-fda-approval-messy-diabetes-market-gets-messier
https://www.businesswire.com/news/home/20171222005054/en/FDA-Approves-SGLT2-Inhibitor-STEGLATRO%E2%84%A2-ertugliflozin-Fixed-Dose/?feedref=JjAwJuNHiystnCoBq_hl-bQQCakZDujohEJegUyaJwquReQ0P23MrIoWkrUSV24ZevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxbNWfZlBntHS6jpH5ROLXsTFMkl05DM8ABqeyBleEmzJA==
https://uk.reuters.com/article/us-merck-co-pfizer-diabetes/u-s-fda-approves-new-diabetes-drug-from-merck-and-pfizer-idUKKBN1EE2QT?rpc=401&